Iván Álvarez-Twose1, María Jara-Acevedo2, José Mário Morgado3, Andrés García-Montero2, Laura Sánchez-Muñoz3, Cristina Teodósio2, Almudena Matito3, Andrea Mayado2, Carolina Caldas2, Manuela Mollejo4, Alberto Orfao2, Luis Escribano5. 1. Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain. Electronic address: ivana@sescam.jccm.es. 2. Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría-NUCLEUS, University of Salamanca, Salamanca, Spain. 3. Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain. 4. Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Pathology Department, Hospital Virgen de la Salud, Toledo, Spain. 5. Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
Abstract
BACKGROUND: Well-differentiated systemic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow (BM) infiltration by mature-appearing mast cells (MCs) often lacking exon 17 KIT mutations. Because of its rarity, the clinical and biological features of WDSM remain poorly defined. OBJECTIVE: We sought to determine the clinical, biological, and molecular features of a cohort of 33 patients with mastocytosis in the skin in association with BM infiltration by well-differentiated MCs and to establish potential diagnostic criteria for WDSM. METHODS: Thirty-three patients with mastocytosis in the skin plus BM aggregates of round, fully granulated MCs lacking strong CD25 and CD2 expression in association with clonal MC features were studied. RESULTS: Our cohort of patients showed female predominance (female/male ratio, 4:1) and childhood onset of the disease (91%) with frequent familial aggregation (39%). Skin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous (12%) mastocytosis. KIT mutations were detected in only 10 (30%) of 33 patients, including the KIT D816V (n = 5), K509I (n = 3), N819Y (n = 1), and I817V (n = 1) mutations. BM MCs displayed a unique immunophenotypic pattern consisting of increased light scatter features, overexpression of cytoplasmic carboxypeptidase, and aberrant expression of CD30, together with absent (79%) or low (21%) positivity for CD25, CD2, or both. Despite only 9 (27%) of 33 patients fulfilling the World Health Organization criteria for SM, our findings allowed us to establish the systemic nature of the disease, which fit with the definition of WDSM. CONCLUSIONS: WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.
BACKGROUND: Well-differentiated systemic mastocytosis (WDSM) is a rare variant of systemic mastocytosis (SM) characterized by bone marrow (BM) infiltration by mature-appearing mast cells (MCs) often lacking exon 17 KIT mutations. Because of its rarity, the clinical and biological features of WDSM remain poorly defined. OBJECTIVE: We sought to determine the clinical, biological, and molecular features of a cohort of 33 patients with mastocytosis in the skin in association with BM infiltration by well-differentiated MCs and to establish potential diagnostic criteria for WDSM. METHODS: Thirty-three patients with mastocytosis in the skin plus BM aggregates of round, fully granulated MCs lacking strong CD25 and CD2 expression in association with clonal MC features were studied. RESULTS: Our cohort of patients showed female predominance (female/male ratio, 4:1) and childhood onset of the disease (91%) with frequent familial aggregation (39%). Skin involvement was heterogeneous, including maculopapular (82%), nodular (6%), and diffuse cutaneous (12%) mastocytosis. KIT mutations were detected in only 10 (30%) of 33 patients, including the KITD816V (n = 5), K509I (n = 3), N819Y (n = 1), and I817V (n = 1) mutations. BM MCs displayed a unique immunophenotypic pattern consisting of increased light scatter features, overexpression of cytoplasmic carboxypeptidase, and aberrant expression of CD30, together with absent (79%) or low (21%) positivity for CD25, CD2, or both. Despite only 9 (27%) of 33 patients fulfilling the World Health Organization criteria for SM, our findings allowed us to establish the systemic nature of the disease, which fit with the definition of WDSM. CONCLUSIONS: WDSM represents a rare clinically and molecularly heterogeneous variant of SM that requires unique diagnostic criteria to avoid a misdiagnosis of cutaneous mastocytosis per current World Health Organization criteria.
Authors: Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe Journal: Cancer Res Date: 2017-03-02 Impact factor: 12.701
Authors: Oscar González-López; Javier I Muñoz-González; Alberto Orfao; Iván Álvarez-Twose; Andrés C García-Montero Journal: Cancers (Basel) Date: 2022-05-18 Impact factor: 6.575
Authors: Joseph D Khoury; Eric Solary; Oussama Abla; Yassmine Akkari; Rita Alaggio; Jane F Apperley; Rafael Bejar; Emilio Berti; Lambert Busque; John K C Chan; Weina Chen; Xueyan Chen; Wee-Joo Chng; John K Choi; Isabel Colmenero; Sarah E Coupland; Nicholas C P Cross; Daphne De Jong; M Tarek Elghetany; Emiko Takahashi; Jean-Francois Emile; Judith Ferry; Linda Fogelstrand; Michaela Fontenay; Ulrich Germing; Sumeet Gujral; Torsten Haferlach; Claire Harrison; Jennelle C Hodge; Shimin Hu; Joop H Jansen; Rashmi Kanagal-Shamanna; Hagop M Kantarjian; Christian P Kratz; Xiao-Qiu Li; Megan S Lim; Keith Loeb; Sanam Loghavi; Andrea Marcogliese; Soheil Meshinchi; Phillip Michaels; Kikkeri N Naresh; Yasodha Natkunam; Reza Nejati; German Ott; Eric Padron; Keyur P Patel; Nikhil Patkar; Jennifer Picarsic; Uwe Platzbecker; Irene Roberts; Anna Schuh; William Sewell; Reiner Siebert; Prashant Tembhare; Jeffrey Tyner; Srdan Verstovsek; Wei Wang; Brent Wood; Wenbin Xiao; Cecilia Yeung; Andreas Hochhaus Journal: Leukemia Date: 2022-06-22 Impact factor: 12.883
Authors: Jeffrey W Craig; Robert P Hasserjian; Annette S Kim; Jon C Aster; Geraldine S Pinkus; Jason L Hornick; David P Steensma; R Coleman Lindsley; Daniel J DeAngelo; Elizabeth A Morgan Journal: Mod Pathol Date: 2020-01-02 Impact factor: 7.842
Authors: Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin Journal: J Allergy Clin Immunol Date: 2021-03-11 Impact factor: 14.290
Authors: Lanshan Huang; Sa A Wang; Sergej Konoplev; Carlos E Bueso-Ramos; Beenu Thakral; Roberto N Miranda; Elias Jabbour; L Jeffrey Medeiros; Rashmi Kanagal-Shamanna Journal: Medicine (Baltimore) Date: 2016-10 Impact factor: 1.889
Authors: Iris M Otani; Ryan W Carroll; Phoebe Yager; Daniela Kroshinsky; Sarah Murphy; Jason L Hornick; Cem Akin; Mariana Castells; Jolan E Walter Journal: Clin Case Rep Date: 2018-07-31
Authors: Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao Journal: Oncotarget Date: 2016-07-19